ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0800

Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease

Gregory McDermott1, Pierre-Antoine Juge2, Keigo Hayashi3, Xiaosong Wang4, Misti Paudel5, Sung Hae Chang6, Qianru Zhang7, Vanessa Kronzer8, Kevin Mueller9, Alene Saavedra9, Katarina Bade9, Grace Qian4, Emily Kowalski9, Kathleen Vanni4, Jing Cui9 and Jeffrey Sparks10, 1Brigham and Women's Hospital, Brookline, MA, 2Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, 3Brigham and Women’s Hospital, Brookline, MA, 4Brigham and Women’s Hospital, Boston, MA, 5Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 6Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 7Harard Medical School, Cambridge, 8Mayo Clinic, Rochester, MN, 9Brigham and Women's Hospital, Boston, MA, 10Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

Meeting: ACR Convergence 2024

Keywords: genetics, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Recent rheumatoid arthritis (RA) genome-wide association studies (GWAS) identified 196 risk loci. Polygenic risk scores (PRS) use GWAS summary statistics to aggregate genome-wide genetic risk for a polygenic disease like RA. We hypothesized that higher RA polygenic risk would be associated with earlier RA onset, seropositive RA, and RA-associated interstitial lung disease (RA-ILD).

Methods: We used a large institutional biobank with over 149,000 patients who provided blood samples and electronic health records data. Participants with RA were identified using a validated algorithm and confirmed to meet RA classification criteria by medical record review. Control patients were participants with available genetic data and no administrative codes for RA or other systemic rheumatic diseases. Genotyping was performed using Illumina MEGA and GSA sequencing arrays. The RA PRS was calculated as a linear sum of beta coefficients of statistically significant loci from summary statistics of a recent transethnic GWAS combined with summary statistics from an association study of human leukocyte antigen alleles and RA risk. We examined associations between the RA PRS and RA diagnosis, seropositivity, age at RA onset, and RA-ILD using logistic regression. In a case-only analysis, we stratified RA patients by RA PRS quartile and examined time to RA diagnosis using multivariable Cox regression. 

Results: We analyzed 1,680 RA cases and 22,185 non-RA controls. Baseline demographics and clinical RA features for cases are detailed in Table 1. The RA PRS was significantly associated with RA diagnosis (OR 1.82 per unit, 95%CI 1.74-1.90 per PRS unit), seropositive RA (OR 2.24, 95%CI 2.11-2.37), and RA diagnosis before age 55 (OR 1.89, 95%CI 1.79 to 2.00) as detailed in Figure 1. The highest quartile of RA PRS was associated with earlier RA diagnosis (median 45.3 years for highest quartile compared to 49.9 years for lowest quartile) as shown in Figure 2. The hazard ratio for time to RA diagnosis was 1.41 (95%CI 1.22-1.62). Among patients with RA, there were no significant associations between RA PRS and presence of RA-ILD (OR 1.02 0.85 to 1.21).

Conclusion: In a large biobank, the RA PRS was associated with RA diagnosis, earlier-onset RA, and seropositivity. Among patients with RA, higher RA polygenic risk was not significantly associated with RA-ILD. RA patients with the highest quartile of genetic risk had RA onset over 4 years earlier than those in the lowest quartile. These findings serve as a “proof-of-concept” demonstrating that the RA PRS can offer important insights about RA timing and clinical presentation.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. McDermott: None; P. Juge: Nordic, 6; K. Hayashi: None; X. Wang: None; M. Paudel: UnitedHealth Group, 11; S. Chang: None; Q. Zhang: None; V. Kronzer: None; K. Mueller: None; A. Saavedra: None; K. Bade: None; G. Qian: None; E. Kowalski: None; K. Vanni: None; J. Cui: None; J. Sparks: Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Gilead, 2, Janssen, 2, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

McDermott G, Juge P, Hayashi K, Wang X, Paudel M, Chang S, Zhang Q, Kronzer V, Mueller K, Saavedra A, Bade K, Qian G, Kowalski E, Vanni K, Cui J, Sparks J. Associations of Rheumatoid Arthritis Polygenic Risk with Age at Onset, Serostatus, and Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-of-rheumatoid-arthritis-polygenic-risk-with-age-at-onset-serostatus-and-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-rheumatoid-arthritis-polygenic-risk-with-age-at-onset-serostatus-and-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology